<DOC>
	<DOC>NCT01527188</DOC>
	<brief_summary>The purpose of this study is to assess the effect of 3 doses of sublingual house dust mite (HDM) tablets versus placebo in the change from baseline of rhinitis total symptom score during the allergen chamber challenge before and after 6 months of treatment.</brief_summary>
	<brief_title>Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite (HDM) Tablets in Allergic Rhinitis Environment Exposure Chamber Model</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>history of HDM rhinitis allergy for &gt; 1 year sensitized to D. pteronyssinus and/or D. farinae RTSS &gt;= 6 at least 2 time points during allergen challenge session co sensitization to other allergen than HDM FEV1 &lt; 80% Asthma GINA &gt; 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>HDM</keyword>
	<keyword>allergic rhinitis</keyword>
</DOC>